Patent classifications
C12N2740/15043
METHODS FOR HIGH-THROUGHPUT SCREENING FOR GENES RELATING TO CELLULAR DIFFERENTIATION
A method of identifying genes relating to cellular differentiation is provided herein. In some embodiments, a method of identifying regulatory genes relating to cellular differentiation includes: contacting a plurality of stem cells with one or more tagged regulatory genes and a selection marker to form a first plurality of transfected/transduced stem cells; selecting the first plurality of transfected/transduced stem cells; culturing the plurality of transfected/transduced stem cells under conditions suitable to allow the plurality of transfected/transduced stem cells to differentiate into a plurality of differentiated cells expressing the one or more tagged regulatory genes; and performing a single cell RNA sequencing on the plurality of differentiated cells to identify genes relating to cellular differentiation.
NIPAH VIRUS ENVELOPE PSEUDOTYPED LENTIVIRUSES AND METHODS OF THEIR USE
The present invention relates to lentiviral particles which have been pseudotyped with Nipah virus (NiV) fusion (F) and attachment (G) glycoproteins (NiVpp-F/G). Additionally, the present invention relates to truncated NiV-F glyocproteins useful in producing such NiVpp lentiviral particles, as well as to additional variant peptides which enhance activity. Further, the present invention relates to methods of using such lentiviral particles or sequences, for example in the treatment of cancer or CNS disorders.
METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATED EXPANSION THEREOF
The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells without prior ex vivo stimulation. The methods typically include engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted CAR. Additional elements of such engineered signaling polypeptides are provided herein, as well as vectors, such as retroviral vectors, packaging cell lines and methods of making the same. Furthermore, recombinant retroviruses and methods of making the same are provided. Numerous controls are provided, including riboswitches that are controlled, for example in vivo, by nucleoside analogues.
Optogenetic probes for measuring membrane potential
The invention provides methods, cells and constructs for optical measurement of membrane potential. These methods can be used in cells that are not accessible to presently available methods using electrodes. The methods can be directed to, for example, high-throughput drug screening assays to determine agents that can affect membrane potential of a target cell.
Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
The present invention provides compositions comprising retroviral vectors, transduced cells, and methods of using the same for gene therapy. In particular, the present invention relates to lentiviral vectors and cells transduced with those vectors to provide gene therapy to subjects having an adrenoleukodystrophy and/or adrenomyeloneuropathy.
Lentiviral vector based immunological compounds against malaria
The invention relates to lentiviral vector particles pseudotyped with a determined heterologous viral envelope protein or viral envelope proteins originating from a RNA virus and which comprise in its genome at least one recombinant polynucleotide encoding at least one polypeptide(s) carrying epitope(s) of an antigen of a Plasmodium parasite capable of infecting a mammalian host. The lentiviral vector particles are used in order to elicit an immunological response against malaria parasites.
Highly inducible dual-promoter lentiviral TET-ON system
The invention relates to expression systems useful for regulated expression of a gene of interest based on the constitutive expression of the original TetR repressor and the expression of the polynucleotide driven by a constitutive promoter operably linked to an operator sequence for a tetracycline operator sequence. The system can be provided as two different polynucleotides or as an all-in-one vector. The invention also relates to vectors, host cells and viral particles according to the invention as well as to the uses thereof for in vitro and in vivo production of products of interest or for therapy.
Systemic and local ex vivo gene therapy of the skeleton
Methods are disclosed herein for increasing bone mass and strength or bone fracture healing in a subject. The methods include administering to the subject a therapeutically effective amount of multipotent stem cells, wherein each multipotent stem cell is transformed with a recombinant nucleic acid molecule comprising a heterologous promoter operably linked to a nucleic acid encoding platelet derived growth factor (PDGF) B, and wherein the multipotent stem cells express a sufficient amount of PDGFB to increase bone mass and strength or bone fracture healing. A lentiviral vector also is disclosed that includes a phosphoglycerate kinase-1 (PGK) promoter operably linked to a nucleic acid encoding PDGFB.
Lymphocytes-antigen presenting cells co-stimulators and uses thereof
Disclosed herein are fusion proteins having a first domain that activates an antigen-presenting cell (APC) (e.g., a dendritic cell) by binding to an activation receptor of the APC, and a second domain that activates an immune effector cell (e.g., a T cell) by targeting a co-stimulatory signaling pathway of the immune effector cell, as well as polynucleotides that encode such fusion proteins. Disclosed herein are also genetically engineered immune effector cells expressing such fusion protein, methods of their production, and their uses in treatment of diseases such as cancers.
NUCLEAR REPROGRAMMING FACTOR AND INDUCED PLURIPOTENT STEM CELLS
A recombinant vector for producing an induced pluripotent stem cell, including an Oct family gene, a Klf family gene, and a Myc family gene, wherein the genes are inserted in the vector and an induced pluripotent stem cell including the recombinant vector. Also disclosed is a method for preparing a recombinant vector for producing an induced pluripotent stem cell, including inserting each of the three genes into a vector such that the genes are capable of expression. Also disclosed are a first recombinant vector for preparing a second recombinant vector for producing an induced pluripotent stem cell, said first recombinant vector including at least two of the following four genes: an Oct family gene, a Klf family gene, a Myc family gene and a Sox family gene. Also disclosed is a method for preparing the first recombinant vector, including inserting the at least two genes into a vector.